Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 59 | 2023 | 2412 | 4.810 |
Why?
|
Hepatitis C, Chronic | 33 | 2022 | 1032 | 3.970 |
Why?
|
Antiviral Agents | 40 | 2022 | 3050 | 3.610 |
Why?
|
End Stage Liver Disease | 16 | 2024 | 369 | 3.550 |
Why?
|
Hepacivirus | 32 | 2022 | 1343 | 3.200 |
Why?
|
Liver Cirrhosis | 47 | 2024 | 1959 | 3.080 |
Why?
|
Hepatitis C | 26 | 2022 | 1597 | 2.810 |
Why?
|
Esophageal and Gastric Varices | 9 | 2023 | 215 | 1.820 |
Why?
|
Ribavirin | 16 | 2019 | 395 | 1.800 |
Why?
|
Hepatorenal Syndrome | 5 | 2023 | 76 | 1.540 |
Why?
|
Carbamates | 7 | 2018 | 191 | 1.530 |
Why?
|
Fluorenes | 7 | 2019 | 160 | 0.990 |
Why?
|
Benzimidazoles | 9 | 2020 | 864 | 0.980 |
Why?
|
Genotype | 18 | 2021 | 13024 | 0.930 |
Why?
|
Gastrointestinal Hemorrhage | 8 | 2023 | 1127 | 0.920 |
Why?
|
Vasoconstrictor Agents | 5 | 2023 | 655 | 0.890 |
Why?
|
Liver Failure | 5 | 2014 | 252 | 0.880 |
Why?
|
Elasticity Imaging Techniques | 8 | 2024 | 398 | 0.870 |
Why?
|
Liver Neoplasms | 16 | 2024 | 4353 | 0.850 |
Why?
|
Hepatitis B | 7 | 2022 | 707 | 0.830 |
Why?
|
Carcinoma, Hepatocellular | 11 | 2024 | 2329 | 0.830 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2023 | 95 | 0.830 |
Why?
|
Uridine Monophosphate | 6 | 2019 | 67 | 0.800 |
Why?
|
Liver Diseases | 7 | 2024 | 1303 | 0.750 |
Why?
|
Waiting Lists | 11 | 2022 | 777 | 0.750 |
Why?
|
Sclerotherapy | 1 | 2019 | 184 | 0.590 |
Why?
|
Tissue Adhesives | 1 | 2019 | 177 | 0.570 |
Why?
|
Liver Diseases, Alcoholic | 2 | 2023 | 157 | 0.560 |
Why?
|
Drug Interactions | 2 | 2021 | 1417 | 0.550 |
Why?
|
Quinoxalines | 6 | 2020 | 296 | 0.510 |
Why?
|
Alcoholism | 3 | 2023 | 1975 | 0.510 |
Why?
|
Postoperative Care | 3 | 2017 | 1470 | 0.510 |
Why?
|
Liver | 17 | 2024 | 7562 | 0.490 |
Why?
|
Tissue Donors | 9 | 2022 | 2395 | 0.490 |
Why?
|
Viral Nonstructural Proteins | 6 | 2018 | 226 | 0.460 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 2014 | 113 | 0.440 |
Why?
|
Drug Therapy, Combination | 16 | 2019 | 6309 | 0.430 |
Why?
|
Macrocyclic Compounds | 3 | 2018 | 68 | 0.420 |
Why?
|
Transaminases | 1 | 2013 | 199 | 0.410 |
Why?
|
Preoperative Care | 3 | 2017 | 2267 | 0.410 |
Why?
|
Sulfonamides | 6 | 2020 | 1984 | 0.400 |
Why?
|
Severity of Illness Index | 14 | 2024 | 15880 | 0.390 |
Why?
|
Middle Aged | 91 | 2024 | 223009 | 0.380 |
Why?
|
Humans | 153 | 2024 | 765968 | 0.370 |
Why?
|
Lypressin | 4 | 2023 | 26 | 0.370 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2012 | 294 | 0.370 |
Why?
|
Fatty Liver | 4 | 2024 | 807 | 0.340 |
Why?
|
Immunosuppressive Agents | 3 | 2017 | 4209 | 0.320 |
Why?
|
Varicose Veins | 2 | 2023 | 158 | 0.310 |
Why?
|
Male | 91 | 2024 | 363698 | 0.310 |
Why?
|
Organ Transplantation | 2 | 2017 | 1174 | 0.310 |
Why?
|
Treatment Outcome | 33 | 2024 | 65188 | 0.300 |
Why?
|
International Normalized Ratio | 2 | 2024 | 381 | 0.300 |
Why?
|
Spouses | 1 | 2011 | 288 | 0.300 |
Why?
|
RNA, Viral | 10 | 2018 | 2864 | 0.300 |
Why?
|
Retrospective Studies | 40 | 2024 | 81514 | 0.300 |
Why?
|
Quality of Life | 6 | 2011 | 13462 | 0.290 |
Why?
|
Fatigue | 3 | 2020 | 1549 | 0.290 |
Why?
|
Yttrium Radioisotopes | 3 | 2024 | 116 | 0.290 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5526 | 0.280 |
Why?
|
Female | 91 | 2024 | 396112 | 0.280 |
Why?
|
Kidney Transplantation | 7 | 2022 | 4270 | 0.270 |
Why?
|
Diagnostic Techniques, Digestive System | 1 | 2007 | 45 | 0.270 |
Why?
|
Drug Administration Schedule | 8 | 2017 | 4850 | 0.270 |
Why?
|
Florida | 3 | 2013 | 416 | 0.260 |
Why?
|
Social Support | 2 | 2013 | 2192 | 0.260 |
Why?
|
Sirolimus | 2 | 2012 | 1545 | 0.250 |
Why?
|
Microspheres | 3 | 2024 | 773 | 0.250 |
Why?
|
Medication Adherence | 2 | 2017 | 2192 | 0.250 |
Why?
|
Adaptation, Psychological | 2 | 2013 | 2660 | 0.250 |
Why?
|
Multivariate Analysis | 8 | 2017 | 12056 | 0.240 |
Why?
|
Drug Resistance, Viral | 4 | 2017 | 866 | 0.230 |
Why?
|
Biliary Tract Diseases | 1 | 2005 | 160 | 0.230 |
Why?
|
Gallbladder Diseases | 1 | 2005 | 139 | 0.220 |
Why?
|
Hepatic Artery | 3 | 2018 | 231 | 0.210 |
Why?
|
Aged | 44 | 2024 | 171117 | 0.210 |
Why?
|
Venous Thrombosis | 2 | 2023 | 1327 | 0.210 |
Why?
|
Primary Graft Dysfunction | 3 | 2013 | 112 | 0.210 |
Why?
|
Adult | 59 | 2024 | 223044 | 0.210 |
Why?
|
Ceftriaxone | 1 | 2024 | 176 | 0.200 |
Why?
|
Recurrence | 8 | 2017 | 8501 | 0.200 |
Why?
|
Drug Combinations | 6 | 2020 | 2077 | 0.200 |
Why?
|
Hepatitis B, Chronic | 2 | 2022 | 412 | 0.200 |
Why?
|
Health Status | 2 | 2013 | 4080 | 0.200 |
Why?
|
Diffusion of Innovation | 1 | 2007 | 721 | 0.190 |
Why?
|
B-Lymphocyte Subsets | 1 | 2003 | 241 | 0.190 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2022 | 129 | 0.190 |
Why?
|
Ascites | 3 | 2023 | 336 | 0.190 |
Why?
|
Interferon Type I | 1 | 2005 | 567 | 0.190 |
Why?
|
Pyrrolidines | 2 | 2020 | 337 | 0.180 |
Why?
|
Sodium | 2 | 2024 | 1591 | 0.180 |
Why?
|
Logistic Models | 6 | 2021 | 13266 | 0.180 |
Why?
|
Cavernous Sinus | 1 | 2001 | 119 | 0.180 |
Why?
|
Creatinine | 2 | 2024 | 1915 | 0.170 |
Why?
|
Hepatic Encephalopathy | 2 | 2018 | 143 | 0.170 |
Why?
|
Secondary Prevention | 3 | 2016 | 1472 | 0.170 |
Why?
|
Hepatitis B Antibodies | 1 | 2000 | 156 | 0.170 |
Why?
|
Recovery of Function | 2 | 2012 | 2966 | 0.170 |
Why?
|
Pilot Projects | 5 | 2024 | 8733 | 0.170 |
Why?
|
Vascular Neoplasms | 1 | 2001 | 167 | 0.170 |
Why?
|
Hepatitis, Alcoholic | 1 | 2021 | 109 | 0.170 |
Why?
|
Time Factors | 12 | 2017 | 40065 | 0.170 |
Why?
|
Organ Preservation Solutions | 1 | 2000 | 105 | 0.170 |
Why?
|
Graft Rejection | 4 | 2017 | 4499 | 0.170 |
Why?
|
Prognosis | 14 | 2023 | 29922 | 0.160 |
Why?
|
Kidney | 3 | 2022 | 7066 | 0.160 |
Why?
|
Mental Health | 1 | 2013 | 3278 | 0.160 |
Why?
|
North America | 1 | 2023 | 1285 | 0.160 |
Why?
|
Alanine Transaminase | 2 | 2015 | 607 | 0.160 |
Why?
|
Viremia | 2 | 2023 | 727 | 0.150 |
Why?
|
Interferon-alpha | 2 | 2014 | 910 | 0.150 |
Why?
|
United States | 18 | 2024 | 72903 | 0.150 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4893 | 0.150 |
Why?
|
Caregivers | 1 | 2011 | 2307 | 0.150 |
Why?
|
Viral Load | 5 | 2017 | 3386 | 0.150 |
Why?
|
Aminoisobutyric Acids | 4 | 2020 | 39 | 0.150 |
Why?
|
Respiratory Insufficiency | 3 | 2022 | 1240 | 0.150 |
Why?
|
Hypertension, Portal | 2 | 2017 | 229 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2001 | 512 | 0.150 |
Why?
|
Substance Abuse, Intravenous | 1 | 2022 | 531 | 0.140 |
Why?
|
Benzofurans | 1 | 2018 | 140 | 0.140 |
Why?
|
Polyethylene Glycols | 2 | 2014 | 1188 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 1 | 2011 | 3230 | 0.140 |
Why?
|
Portal Pressure | 1 | 2017 | 62 | 0.140 |
Why?
|
New Zealand | 2 | 2014 | 359 | 0.140 |
Why?
|
Risk Assessment | 7 | 2021 | 24282 | 0.140 |
Why?
|
Hepatic Veins | 1 | 2017 | 112 | 0.140 |
Why?
|
Endoscopy, Digestive System | 1 | 2019 | 358 | 0.130 |
Why?
|
Balloon Occlusion | 1 | 2017 | 129 | 0.130 |
Why?
|
Cholangiocarcinoma | 2 | 2021 | 578 | 0.130 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 836 | 0.130 |
Why?
|
Leucine | 4 | 2020 | 546 | 0.130 |
Why?
|
Cyclopropanes | 4 | 2020 | 437 | 0.130 |
Why?
|
Hepatitis C Antibodies | 1 | 2016 | 151 | 0.130 |
Why?
|
Proline | 4 | 2020 | 453 | 0.130 |
Why?
|
Lactams, Macrocyclic | 4 | 2020 | 318 | 0.130 |
Why?
|
Interferons | 2 | 2017 | 714 | 0.130 |
Why?
|
Drug Therapy | 1 | 2019 | 504 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2023 | 1316 | 0.130 |
Why?
|
Hepatitis, Chronic | 2 | 2011 | 53 | 0.130 |
Why?
|
Lamivudine | 2 | 2010 | 368 | 0.130 |
Why?
|
Cystic Fibrosis | 1 | 2005 | 1287 | 0.130 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 626 | 0.120 |
Why?
|
Antigens, CD | 2 | 2003 | 4025 | 0.120 |
Why?
|
Feasibility Studies | 2 | 2024 | 5302 | 0.120 |
Why?
|
Ultrasonography, Interventional | 1 | 2024 | 1531 | 0.120 |
Why?
|
Predictive Value of Tests | 9 | 2024 | 15398 | 0.120 |
Why?
|
Albumins | 3 | 2023 | 577 | 0.120 |
Why?
|
Mood Disorders | 2 | 2013 | 1128 | 0.120 |
Why?
|
Stress, Psychological | 1 | 2011 | 4533 | 0.120 |
Why?
|
Cohort Studies | 16 | 2021 | 41649 | 0.120 |
Why?
|
Neurotransmitter Agents | 1 | 2019 | 663 | 0.120 |
Why?
|
Graft Occlusion, Vascular | 1 | 2018 | 540 | 0.120 |
Why?
|
Ammonia | 1 | 2016 | 244 | 0.120 |
Why?
|
Death | 2 | 2011 | 686 | 0.120 |
Why?
|
Cell Separation | 1 | 2000 | 1718 | 0.120 |
Why?
|
Cytokines | 3 | 2019 | 7421 | 0.120 |
Why?
|
Patient Selection | 4 | 2018 | 4255 | 0.120 |
Why?
|
Cholangitis, Sclerosing | 1 | 2017 | 177 | 0.120 |
Why?
|
Blood Chemical Analysis | 2 | 2015 | 433 | 0.120 |
Why?
|
Nephrectomy | 1 | 2020 | 927 | 0.120 |
Why?
|
Graft Survival | 6 | 2018 | 3890 | 0.120 |
Why?
|
Angioplasty, Balloon | 1 | 2018 | 608 | 0.120 |
Why?
|
Apolipoproteins | 1 | 2016 | 327 | 0.110 |
Why?
|
Portal Vein | 3 | 2023 | 435 | 0.110 |
Why?
|
Bronchial Neoplasms | 1 | 2014 | 109 | 0.110 |
Why?
|
Transplants | 1 | 2016 | 208 | 0.110 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2015 | 238 | 0.110 |
Why?
|
HIV Infections | 6 | 2017 | 17533 | 0.110 |
Why?
|
Lipase | 1 | 2016 | 320 | 0.110 |
Why?
|
Risk Factors | 16 | 2022 | 74840 | 0.100 |
Why?
|
Aspartate Aminotransferases | 1 | 2014 | 415 | 0.100 |
Why?
|
Epidermal Growth Factor | 1 | 2016 | 698 | 0.100 |
Why?
|
Membrane Proteins | 2 | 2016 | 7851 | 0.100 |
Why?
|
Postoperative Complications | 6 | 2017 | 15747 | 0.100 |
Why?
|
Glomerulonephritis, IGA | 1 | 2013 | 62 | 0.100 |
Why?
|
Lymphocytes | 1 | 2000 | 2599 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 674 | 0.100 |
Why?
|
BK Virus | 1 | 2013 | 121 | 0.100 |
Why?
|
Imidazoles | 1 | 2018 | 1162 | 0.100 |
Why?
|
Activities of Daily Living | 2 | 2011 | 2415 | 0.100 |
Why?
|
Thrombosis | 3 | 2022 | 2949 | 0.100 |
Why?
|
C-Reactive Protein | 1 | 2024 | 3850 | 0.100 |
Why?
|
Biopsy | 6 | 2017 | 6763 | 0.090 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 580 | 0.090 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3432 | 0.090 |
Why?
|
Fibrosis | 3 | 2024 | 2070 | 0.090 |
Why?
|
Proton Pump Inhibitors | 1 | 2016 | 553 | 0.090 |
Why?
|
Hepatitis B virus | 2 | 2012 | 530 | 0.090 |
Why?
|
Interleukins | 1 | 2016 | 791 | 0.090 |
Why?
|
Socioeconomic Factors | 3 | 2019 | 7838 | 0.090 |
Why?
|
Polyomavirus Infections | 1 | 2013 | 194 | 0.090 |
Why?
|
Prevalence | 3 | 2021 | 15842 | 0.090 |
Why?
|
Cold Ischemia | 1 | 2011 | 72 | 0.090 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 1403 | 0.090 |
Why?
|
Aged, 80 and over | 9 | 2020 | 59489 | 0.090 |
Why?
|
Health Personnel | 2 | 2023 | 3390 | 0.090 |
Why?
|
Tumor Virus Infections | 1 | 2013 | 440 | 0.080 |
Why?
|
Platelet Count | 1 | 2013 | 782 | 0.080 |
Why?
|
Disease Management | 2 | 2020 | 2535 | 0.080 |
Why?
|
Kidney Neoplasms | 2 | 2020 | 4274 | 0.080 |
Why?
|
Renal Replacement Therapy | 2 | 2023 | 281 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6499 | 0.080 |
Why?
|
Single-Blind Method | 1 | 2013 | 1589 | 0.080 |
Why?
|
Transplantation, Homologous | 2 | 2016 | 4860 | 0.080 |
Why?
|
Young Adult | 11 | 2022 | 59889 | 0.080 |
Why?
|
Abdomen | 1 | 2015 | 1134 | 0.080 |
Why?
|
Keratin-18 | 1 | 2009 | 37 | 0.080 |
Why?
|
Polytetrafluoroethylene | 1 | 2010 | 238 | 0.080 |
Why?
|
Pulmonary Veins | 1 | 2015 | 757 | 0.080 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3928 | 0.080 |
Why?
|
Affective Symptoms | 1 | 2011 | 417 | 0.080 |
Why?
|
Postoperative Period | 1 | 2013 | 1816 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1365 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2023 | 12240 | 0.080 |
Why?
|
Attitude to Death | 1 | 2011 | 399 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2022 | 2921 | 0.070 |
Why?
|
Thrombectomy | 2 | 2023 | 681 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2016 | 9249 | 0.070 |
Why?
|
Europe | 1 | 2014 | 3423 | 0.070 |
Why?
|
Primary Health Care | 2 | 2021 | 4736 | 0.070 |
Why?
|
Linear Models | 2 | 2021 | 5876 | 0.070 |
Why?
|
Ventilator Weaning | 1 | 2008 | 170 | 0.070 |
Why?
|
Th1 Cells | 2 | 2002 | 1039 | 0.070 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 1731 | 0.070 |
Why?
|
Sensitivity and Specificity | 5 | 2015 | 14652 | 0.070 |
Why?
|
Cyclosporine | 1 | 2009 | 778 | 0.070 |
Why?
|
Methylene Blue | 1 | 2007 | 157 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 953 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1078 | 0.070 |
Why?
|
Personal Satisfaction | 1 | 2011 | 641 | 0.070 |
Why?
|
B-Lymphocytes | 1 | 2000 | 4778 | 0.070 |
Why?
|
Pulmonary Artery | 1 | 2015 | 1935 | 0.060 |
Why?
|
Follow-Up Studies | 8 | 2018 | 39193 | 0.060 |
Why?
|
Tissue and Organ Procurement | 3 | 2012 | 989 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5444 | 0.060 |
Why?
|
Survival Rate | 6 | 2021 | 12795 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2001 | 4044 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3529 | 0.060 |
Why?
|
Immunoglobulins | 2 | 2010 | 852 | 0.060 |
Why?
|
Liver Function Tests | 2 | 2005 | 525 | 0.060 |
Why?
|
Patient Satisfaction | 2 | 2023 | 3475 | 0.060 |
Why?
|
Tacrolimus | 1 | 2009 | 753 | 0.060 |
Why?
|
Fatal Outcome | 3 | 2014 | 1831 | 0.060 |
Why?
|
Intubation | 1 | 2005 | 141 | 0.060 |
Why?
|
SEER Program | 2 | 2021 | 1446 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8041 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5753 | 0.060 |
Why?
|
Viral Envelope Proteins | 2 | 2013 | 640 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10383 | 0.060 |
Why?
|
Coronary Artery Disease | 2 | 2021 | 6544 | 0.060 |
Why?
|
Information Storage and Retrieval | 2 | 2021 | 834 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3181 | 0.060 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6493 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1940 | 0.060 |
Why?
|
Biliary Tract | 1 | 2005 | 137 | 0.060 |
Why?
|
Survival Analysis | 4 | 2020 | 10070 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 4 | 2015 | 20659 | 0.060 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2002 | 318 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5719 | 0.060 |
Why?
|
Nitric Oxide Synthase | 1 | 2007 | 911 | 0.060 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2005 | 132 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20124 | 0.050 |
Why?
|
Boston | 3 | 2012 | 9338 | 0.050 |
Why?
|
Genes, MHC Class I | 1 | 2004 | 236 | 0.050 |
Why?
|
Gallbladder | 1 | 2005 | 308 | 0.050 |
Why?
|
Phantoms, Imaging | 1 | 2012 | 2475 | 0.050 |
Why?
|
Genes, MHC Class II | 1 | 2004 | 433 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2002 | 2210 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4900 | 0.050 |
Why?
|
Ontario | 1 | 2024 | 402 | 0.050 |
Why?
|
Adolescent | 8 | 2021 | 88835 | 0.050 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2022 | 84 | 0.050 |
Why?
|
Attitude to Health | 1 | 2011 | 2020 | 0.050 |
Why?
|
Reoperation | 3 | 2018 | 4294 | 0.050 |
Why?
|
Terminal Care | 1 | 2014 | 1774 | 0.050 |
Why?
|
Systems Analysis | 1 | 2023 | 168 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5891 | 0.050 |
Why?
|
Tissue and Organ Harvesting | 1 | 2005 | 373 | 0.050 |
Why?
|
Endoscopy | 3 | 2017 | 1841 | 0.050 |
Why?
|
K562 Cells | 2 | 2002 | 649 | 0.050 |
Why?
|
Hypotension | 1 | 2008 | 885 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 439 | 0.050 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2005 | 452 | 0.050 |
Why?
|
Complement Pathway, Classical | 1 | 2001 | 82 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 7049 | 0.050 |
Why?
|
Immunophenotyping | 3 | 2002 | 1866 | 0.050 |
Why?
|
Viral Core Proteins | 1 | 2002 | 158 | 0.050 |
Why?
|
Suction | 1 | 2022 | 265 | 0.050 |
Why?
|
Odds Ratio | 1 | 2013 | 9649 | 0.050 |
Why?
|
Diffusion Tensor Imaging | 1 | 2012 | 2410 | 0.050 |
Why?
|
Pentanoic Acids | 1 | 2020 | 19 | 0.050 |
Why?
|
Complement C4 | 1 | 2001 | 208 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2013 | 4040 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2021 | 2229 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26318 | 0.040 |
Why?
|
Raffinose | 1 | 2000 | 57 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8875 | 0.040 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1628 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2004 | 4405 | 0.040 |
Why?
|
Device Removal | 1 | 2005 | 646 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 2233 | 0.040 |
Why?
|
Blood Component Transfusion | 1 | 2021 | 138 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2021 | 12437 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5993 | 0.040 |
Why?
|
Donor Selection | 1 | 2022 | 242 | 0.040 |
Why?
|
Prospective Studies | 6 | 2024 | 54802 | 0.040 |
Why?
|
Apolipoproteins B | 1 | 2021 | 384 | 0.040 |
Why?
|
Neutropenia | 1 | 2005 | 893 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 307 | 0.040 |
Why?
|
Morbidity | 1 | 2005 | 1749 | 0.040 |
Why?
|
Palliative Care | 1 | 2014 | 3645 | 0.040 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2023 | 445 | 0.040 |
Why?
|
Alanine | 1 | 2022 | 612 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 703 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2002 | 592 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 621 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 4 | 2023 | 36532 | 0.040 |
Why?
|
Rheumatoid Factor | 1 | 2000 | 183 | 0.040 |
Why?
|
Medicare | 3 | 2023 | 6823 | 0.040 |
Why?
|
Allopurinol | 1 | 2000 | 203 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4642 | 0.040 |
Why?
|
Living Donors | 1 | 2023 | 645 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2023 | 751 | 0.040 |
Why?
|
Lymphoid Tissue | 1 | 2000 | 444 | 0.040 |
Why?
|
Constriction, Pathologic | 2 | 2018 | 1105 | 0.040 |
Why?
|
Acute Disease | 2 | 2017 | 7232 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3236 | 0.040 |
Why?
|
Necrosis | 1 | 2022 | 1617 | 0.040 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2002 | 825 | 0.040 |
Why?
|
Angiography | 1 | 2023 | 1581 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13648 | 0.040 |
Why?
|
Plasma | 1 | 2021 | 579 | 0.040 |
Why?
|
Glutathione | 1 | 2000 | 588 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2014 | 6069 | 0.040 |
Why?
|
Heart Failure | 1 | 2022 | 11840 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2014 | 3800 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2005 | 1171 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8529 | 0.030 |
Why?
|
Angiography, Digital Subtraction | 1 | 2018 | 332 | 0.030 |
Why?
|
Substance-Related Disorders | 1 | 2013 | 4416 | 0.030 |
Why?
|
Osteolysis | 1 | 1999 | 271 | 0.030 |
Why?
|
Lipoproteins | 1 | 2021 | 866 | 0.030 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 1999 | 361 | 0.030 |
Why?
|
Lipoprotein(a) | 1 | 2021 | 488 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2012 | 22223 | 0.030 |
Why?
|
Mesenteric Veins | 1 | 1997 | 86 | 0.030 |
Why?
|
Endopeptidases | 1 | 2000 | 759 | 0.030 |
Why?
|
Phenotype | 1 | 2014 | 16721 | 0.030 |
Why?
|
Antigens, CD19 | 1 | 2000 | 443 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2005 | 4108 | 0.030 |
Why?
|
Israel | 1 | 2019 | 725 | 0.030 |
Why?
|
Pain | 1 | 2011 | 5077 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2000 | 1162 | 0.030 |
Why?
|
Pruritus | 1 | 2020 | 378 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2002 | 1415 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 16047 | 0.030 |
Why?
|
HLA-DR Antigens | 3 | 2004 | 608 | 0.030 |
Why?
|
Serine Proteases | 1 | 2016 | 43 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2023 | 2424 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2002 | 1365 | 0.030 |
Why?
|
Research Design | 1 | 2012 | 6209 | 0.030 |
Why?
|
Flow Cytometry | 3 | 2002 | 5881 | 0.030 |
Why?
|
Antibody Formation | 1 | 2000 | 1391 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2000 | 1441 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1511 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2024 | 1217 | 0.030 |
Why?
|
Alleles | 2 | 2004 | 6897 | 0.030 |
Why?
|
Adenosine | 1 | 2000 | 806 | 0.030 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 2203 | 0.030 |
Why?
|
Body Mass Index | 2 | 2010 | 13039 | 0.030 |
Why?
|
Interferon-gamma | 2 | 2002 | 3160 | 0.030 |
Why?
|
Software | 2 | 2024 | 4462 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2016 | 416 | 0.030 |
Why?
|
Vascular Patency | 1 | 2018 | 912 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11206 | 0.030 |
Why?
|
Patient Compliance | 1 | 2005 | 2692 | 0.030 |
Why?
|
HIV | 2 | 2014 | 1585 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2002 | 2002 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2002 | 1811 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 138 | 0.030 |
Why?
|
Ischemia | 1 | 2023 | 1909 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2021 | 1741 | 0.030 |
Why?
|
Cholestasis | 1 | 2017 | 386 | 0.030 |
Why?
|
Gastroenterology | 1 | 2000 | 594 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15652 | 0.030 |
Why?
|
Drug Approval | 1 | 2021 | 818 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2002 | 2570 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2017 | 746 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2017 | 5343 | 0.030 |
Why?
|
Spain | 1 | 2014 | 483 | 0.030 |
Why?
|
Models, Economic | 1 | 2017 | 716 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1944 | 0.030 |
Why?
|
Advance Directives | 1 | 2014 | 251 | 0.030 |
Why?
|
Heart Diseases | 1 | 2005 | 2821 | 0.030 |
Why?
|
Cholesterol | 1 | 2021 | 2898 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 878 | 0.020 |
Why?
|
Vaccination | 1 | 2004 | 3426 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2017 | 11022 | 0.020 |
Why?
|
Disease Progression | 3 | 2016 | 13632 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2010 | 0.020 |
Why?
|
Treatment Failure | 1 | 2018 | 2652 | 0.020 |
Why?
|
Hemorrhage | 1 | 2024 | 3461 | 0.020 |
Why?
|
Neoplasms | 1 | 2021 | 22340 | 0.020 |
Why?
|
Headache | 1 | 2020 | 1259 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2017 | 2910 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2012 | 6203 | 0.020 |
Why?
|
Oligopeptides | 1 | 2016 | 1192 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2018 | 2194 | 0.020 |
Why?
|
Thrombopoietin | 1 | 2013 | 225 | 0.020 |
Why?
|
Child | 4 | 2023 | 80564 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3211 | 0.020 |
Why?
|
Cell Survival | 1 | 2000 | 5747 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1737 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 2017 | 1470 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2936 | 0.020 |
Why?
|
Bone Marrow | 1 | 2000 | 2921 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2021 | 4493 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2895 | 0.020 |
Why?
|
Chronic Disease | 1 | 2024 | 9347 | 0.020 |
Why?
|
Databases, Factual | 2 | 2020 | 8067 | 0.020 |
Why?
|
Echocardiography | 1 | 2022 | 5045 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7425 | 0.020 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2009 | 150 | 0.020 |
Why?
|
Bronchoscopy | 1 | 2014 | 909 | 0.020 |
Why?
|
Anisotropy | 1 | 2012 | 1282 | 0.020 |
Why?
|
Computer Simulation | 2 | 2012 | 6255 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 4015 | 0.020 |
Why?
|
Hepatitis | 1 | 2010 | 227 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5596 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2000 | 3401 | 0.020 |
Why?
|
Organ Size | 1 | 2013 | 2260 | 0.020 |
Why?
|
Interleukin-10 | 2 | 2004 | 1183 | 0.020 |
Why?
|
Atrophy | 1 | 2013 | 1635 | 0.020 |
Why?
|
Colonoscopy | 1 | 2015 | 1406 | 0.020 |
Why?
|
Age Factors | 3 | 2009 | 18380 | 0.020 |
Why?
|
Genetic Variation | 1 | 2002 | 6610 | 0.020 |
Why?
|
Hepatitis B e Antigens | 1 | 2007 | 135 | 0.020 |
Why?
|
DNA, Viral | 1 | 2014 | 2199 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 12768 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2003 | 0.020 |
Why?
|
Lectins | 1 | 2009 | 487 | 0.020 |
Why?
|
Up-Regulation | 1 | 2016 | 4137 | 0.020 |
Why?
|
Adipokines | 1 | 2009 | 308 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2012 | 1238 | 0.020 |
Why?
|
Stents | 1 | 2018 | 3213 | 0.020 |
Why?
|
Renal Circulation | 1 | 2007 | 289 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2844 | 0.020 |
Why?
|
Viruses | 1 | 2010 | 371 | 0.020 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2010 | 548 | 0.020 |
Why?
|
Radiography | 2 | 2009 | 6919 | 0.020 |
Why?
|
Insulin | 1 | 2000 | 6599 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6832 | 0.020 |
Why?
|
Hyaluronic Acid | 1 | 2009 | 484 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 12976 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3956 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 1997 | 2226 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10729 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2000 | 18973 | 0.010 |
Why?
|
HLA-A3 Antigen | 1 | 2004 | 34 | 0.010 |
Why?
|
Pancreas Transplantation | 1 | 2005 | 194 | 0.010 |
Why?
|
JC Virus | 1 | 2005 | 87 | 0.010 |
Why?
|
Rho(D) Immune Globulin | 1 | 2004 | 34 | 0.010 |
Why?
|
Resource Allocation | 1 | 2007 | 354 | 0.010 |
Why?
|
Cardiac Output | 1 | 2007 | 840 | 0.010 |
Why?
|
Reperfusion Injury | 1 | 2011 | 1042 | 0.010 |
Why?
|
Comorbidity | 1 | 2019 | 10563 | 0.010 |
Why?
|
Virus Diseases | 1 | 2010 | 718 | 0.010 |
Why?
|
HLA-A Antigens | 1 | 2004 | 223 | 0.010 |
Why?
|
Algorithms | 1 | 2024 | 14071 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 2310 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 2495 | 0.010 |
Why?
|
Contrast Media | 1 | 2017 | 5329 | 0.010 |
Why?
|
Registries | 1 | 2020 | 8297 | 0.010 |
Why?
|
Cause of Death | 1 | 2014 | 3708 | 0.010 |
Why?
|
Receptors, KIR2DL1 | 1 | 2002 | 13 | 0.010 |
Why?
|
Receptors, KIR2DL3 | 1 | 2002 | 15 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily D | 1 | 2002 | 30 | 0.010 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 2002 | 42 | 0.010 |
Why?
|
Mast-Cell Sarcoma | 1 | 2002 | 46 | 0.010 |
Why?
|
Receptors, KIR3DL1 | 1 | 2002 | 27 | 0.010 |
Why?
|
Drug Contamination | 1 | 2004 | 152 | 0.010 |
Why?
|
Mental Disorders | 2 | 2017 | 6853 | 0.010 |
Why?
|
Brain | 2 | 2012 | 27171 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8703 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3685 | 0.010 |
Why?
|
Receptors, KIR | 1 | 2002 | 114 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2699 | 0.010 |
Why?
|
Blood Pressure | 2 | 2008 | 8532 | 0.010 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2001 | 91 | 0.010 |
Why?
|
Electroencephalography | 1 | 2017 | 6273 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12509 | 0.010 |
Why?
|
Glycoproteins | 1 | 2009 | 2195 | 0.010 |
Why?
|
Interleukin-5 | 1 | 2002 | 268 | 0.010 |
Why?
|
Critical Illness | 1 | 2014 | 2744 | 0.010 |
Why?
|
ROC Curve | 1 | 2009 | 3620 | 0.010 |
Why?
|
Carcinoid Tumor | 1 | 2002 | 225 | 0.010 |
Why?
|
Edetic Acid | 1 | 2001 | 274 | 0.010 |
Why?
|
Intubation, Intratracheal | 1 | 2008 | 1303 | 0.010 |
Why?
|
Nucleotides | 1 | 2002 | 451 | 0.010 |
Why?
|
HLA-DQ Antigens | 1 | 2000 | 190 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2005 | 866 | 0.010 |
Why?
|
Incidence | 2 | 2008 | 21480 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2002 | 1347 | 0.010 |
Why?
|
Cell Count | 1 | 2002 | 1823 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 813 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2000 | 726 | 0.010 |
Why?
|
Ultrasonography, Doppler | 1 | 2000 | 460 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 1600 | 0.010 |
Why?
|
Cold Temperature | 1 | 2001 | 794 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2686 | 0.010 |
Why?
|
Mice | 2 | 2002 | 81819 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6547 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6113 | 0.010 |
Why?
|
Phylogeny | 1 | 2002 | 2832 | 0.010 |
Why?
|
Monocytes | 1 | 2004 | 2595 | 0.010 |
Why?
|
Evolution, Molecular | 1 | 2002 | 1889 | 0.010 |
Why?
|
Haplotypes | 1 | 2000 | 2728 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2010 | 14751 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 1997 | 990 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4908 | 0.010 |
Why?
|
Animals | 2 | 2002 | 168764 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2002 | 13400 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 17594 | 0.010 |
Why?
|
Child, Preschool | 1 | 2012 | 42500 | 0.000 |
Why?
|
Bone and Bones | 1 | 1999 | 2554 | 0.000 |
Why?
|
Inflammation | 1 | 2007 | 10850 | 0.000 |
Why?
|
Bone Density | 1 | 1999 | 3491 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 2002 | 6364 | 0.000 |
Why?
|
Colorectal Neoplasms | 1 | 2002 | 6942 | 0.000 |
Why?
|
Cell Differentiation | 1 | 2000 | 11641 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2000 | 18071 | 0.000 |
Why?
|